IA
MTNB icon

IFG Advisory’s Matinas BioPharma MTNB Stock Holding History

IFG Advisory’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6 Buy
+10
New +$6 ﹤0.01% 2355

Other funds holding MTNB

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

IFG Advisory's MTNB Position: Q2 2026 in Review

IFG Advisory opened a new position in Matinas BioPharma (MTNB) in Q2 2026: 10 shares worth $6. The stake represents ﹤0.01% of the portfolio and ranks #2355 among its holdings.

25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

  • IFG Advisory held 10 shares of Matinas BioPharma worth $6 as of Q2 2026.
  • Matinas BioPharma was a new IFG Advisory position in Q2 2026.
  • Matinas BioPharma made up ﹤0.01% of IFG Advisory's portfolio in Q2 2026, its #2355 holding.
  • 25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on IFG Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.